





		JOB OFFER				
REFERENCE		OPENING DATE		DEADLINE		
2020.392		30/09/2024		09/10/2024		
	PR	OFILE REQUIRE	MENTS			
	EXC	LUSIVE REQUIREM	ENTS: (1)			
ACADEMIC DEGREE	Degree/Equivalent (Justification must be provided with the application).					
	١	ALUED MERITS /S	KYLLS			
FURTHER - Advanced level of office automation - Knowledge in PRL						
EXPERIENCE	- Experience in handling CRDe and query resolution.					
OTHERS		of haematology (M				
CONTRACT INFORMATION						
TYPE OF CONTRACT		EXPECTED INCOR DATE		JOB STATUS		
<b>Contract for scientific-technical activities</b> (article 23.bis of Law 14/2011, of June 1, on Science, Technology and Innovation)		October/Nov	vember	Full time. 1575 hours per year (aprox. 35h/week)		
ANNUAL GROSS SALARY		DURATION OF THE CONTRACT				
22.081,74 € without prejudice to the basic update established in state legislation for 2024.		<b>Indefinite</b> (linked to the duration of the project or to external financing or financing from public grants in full competition).				
WORK LOCATIONS		UNIT/DEPARTMENT				
Ward 20, Haematology consultation rooms and floor. Clinical Trials Unit		Haematology/Clinical Trials				
		JOB DETAIL	S			
		OFFER DESCRIPT	ION			
	Re	esearch support tec	hnician			
FUNCTIONS						
data entry. Processing and sendi Carrying out specific Knowing the protoc procedures. Preparing monitoring Educating and monit visits in the hospital Provide support to th	ing biological s training relate ols of the di visits and ens oring the patie e researcher a	samples. ed to the position. ifferent clinical tri suring the correct r ent in the use of tec as study coordinato	als of the s naintenance chnology (tab	liance with the metric schedule for service, test schedules and their of patient files. plet, phone) within the scheduled		
PRINCIPAL INVESTIGATOR	EARCH GROUP		RESEARCH PROJECT			
RESPONSABLE Dr Enrique María Ocio : Miguel	San Haemate Neoplas Transpla Haemate Progenit	ological ms and antation of opoietic	evaluate th cell redirec Teclistamat refractory n	Phase 1 dose-escalation trial to e combination of two bispecific T- tion antibodies, Talquetamab and D, in subjects with relapsed or nultiple myeloma.		

## **RECRUITMENT INFORMATION**

Av. Cardenal Herrera Oria s/n | w 39011 Santander - España | Te

s/n www.idival.org Tel. +34 942 31 55 15 Fundación Instituto de Investigación Marqués de Valdecilla CIF: G 39788773









SELECTION PROCESS STAGES	EMPLOYMENT EXCHANGE			
<ol> <li>Admission of applications</li> <li>Competition phase.</li> <li>Interview pase: maximum phase: 30.</li> <li>Report of the Tribunal.</li> <li>Resolution.</li> <li><u>Note:</u> in order for candidates purposes, they must have a total sector.</li> </ol>	ΝΟΤ			
	SE	LECTION BOARD		
President: Enrique María Ocio S Member: Arancha Bermúdez Ro Member and secretary: Merce	dríguez, Head of Sect	tion.		
	VALU	IATION OF MERITS		
MERITS	EVALUATION	SCORE		MAXIMUM
Advanced level of office automation	Curricular	Merit fullfilment	Yes/No	10
Knowledge in PRL	Curricular	Merit fullfilment	Yes/No	5
Experience in handling CRDe and query resolution	Curricular	Merit fullfilment	Yes/No	10
Database maintenance	Curricular	Merit fullfilment	Yes/No	10
Demonstrable experience in First in Human trials in haematology	Curricular	Merit fullfilment	Yes/No	10
Demonstrable experience in CAR-T therapy trials in haematology	Curricular	Merit fullfilment	Yes/No	10
Knowledge of haematology (MM, Lymphoma, MDS)	Curricular	Merit fullfilment	Yes/No	5
		FINAL SCORE		
MAXIMUM TOTAL SCORE BY N	60			
MAXIMUM TOTAL SCORE IN I	NTERVIEW			40

(1) Not subsanable

(2) See duration of each phase in the document "Selection Process"

In compliance with the provisions of Article 11 of Organic Law 32018, you are informed that the person responsible for the processing of your personal data is the MARQUES DE VALDECILLA INSTITUTE OF INVESTIGATION FOUNDATION (IDIVAL), your data will be treated in order to be treated to the extent that they were necessary or convenient for the development of the legal relationship established between the parties. You can exercise your rights of access, rectification, deletion, opposition, portability or limitation of the treatment, by contacting the IDIVAL FOUNDATION at the following address: AVDA. CARDENAL HERRERA ORIA, S / N 39007, SANTANDER. More information at <u>www.idival.org/es/Politica-de-Privacidad</u>

Santander as of the date of electronic signature

Fdo. Francisco Galo Peralta Fernandez

Av. Cardenal Herrera Oria s/n 39011 Santander - España

www.idival.org Tel. +34 942 31 55 15 Fundación Instituto de Investigación Marqués de Valdecilla CIF: G 39788773

CSV : GEN-313f-f81b-2732-3337-7fe1-c3f8-6720-d581 DIRECCIÓN DE VALIDACIÓN : https://portafirmas.redsara.es/pf/valida FIRMANTE(1) : FRANCISCO GALO PERALTA FERNANDEZ | FECHA : 30/09/2024 08:43 | Sin acción específica

